Laureano Simón

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment.Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma.Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumorinvasiveness, drug resistance and immunosuppression.Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.